Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-04-19 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
独立董事工作制度（2024年4月修订）
Governance Information Classification · 95% confidence The document is titled "独立董事工作制度" which translates to "Independent Director Work System" and contains detailed provisions about the roles, responsibilities, appointment, and working conditions of independent directors at Yifan Pharmaceutical Co., Ltd. It references relevant laws, regulations, and governance practices. The content is focused on governance structure and internal rules related to the board and independent directors rather than financial results, audit opinions, or shareholder meeting materials. There is no indication that this is an announcement or a report publication notice. The document is comprehensive and regulatory in nature, detailing governance practices and board management. Therefore, it fits best under Governance Information (CGR).
2024-04-19 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 11th meeting of the 8th Board of Directors of 亿帆医药股份有限公司, held in April 2024. It includes approvals of the 2023 annual president's work report, board work report, financial statements, annual report and its summary, profit distribution plan, internal audit reports, internal control self-evaluation, and other governance-related documents. It also references the 2023 annual report and other reports that are published separately on the official information disclosure platform (巨潮资讯网). The document is not the annual report itself but an announcement of the board meeting resolutions including approval of the annual report and related documents. The document length is about 5581 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of board meeting resolutions and references to other filings, not the full annual report or financial statements themselves.
2024-04-19 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed company information, business overview, industry position, and key financial data for the year 2023. The length is substantial (15,000 characters), indicating it is a report rather than a brief announcement. The content includes comprehensive financial and operational data typical of an Annual Report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-19 Chinese
投资管理制度(2024年4月修订)
Governance Information Classification · 95% confidence The document is titled '投资管理制度' (Investment Management System) and contains detailed internal rules and procedures regarding investment decision-making authority, voting on investment matters, and disposal of investments within the company. It references company governance documents and legal regulations, indicating it is a governance-related internal policy document. The content is about the company's internal governance structure and investment decision processes rather than financial results, audit opinions, or shareholder meeting materials. It is not a financial report, earnings release, or regulatory announcement. Therefore, the document best fits the category of Governance Information (CGR). The document length is under 5,000 characters, but it is a substantive policy document, not a mere announcement, so it is not RPA or RNS.
2024-04-19 Chinese
年度募集资金使用鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report by a certified public accounting firm on the special report regarding the storage and use of raised funds by 亿帆医药股份有限公司 for the year 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to the management and use of raised funds. The document includes detailed financial data on the amount raised, usage, balances, and compliance with regulatory requirements. It is not a full annual report, earnings release, or general regulatory filing but a specific audit/assurance report on the use of raised funds. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on a specific financial aspect (raised funds usage) and not the full annual report or other categories. The document length and detail confirm it is the report itself, not just an announcement or certification letter. FY 2023
2024-04-19 Chinese
审计委员会议事规则（2024年4月修订）
Governance Information Classification · 95% confidence The document is titled "审计委员会议事规则" which translates to "Audit Committee Meeting Rules" and details the composition, responsibilities, meeting procedures, and disclosure requirements of the audit committee of Yifan Pharmaceutical Co., Ltd. It references regulatory frameworks such as the Company Law of China, Shenzhen Stock Exchange listing rules, and governance codes. The content focuses on the internal governance and operational rules of the audit committee rather than presenting financial statements, audit opinions, or financial results. It is a governance-related document outlining the audit committee's structure and duties, not an audit report or annual report itself. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.